Medicure Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCUJF research report →
About the company
Medicure Inc. operates as a biopharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the cardiovascular market, primarily serving Canada and the United States. Among its key offerings is AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist specifically designed to manage acute coronary syndrome, encompassing conditions like unstable angina and non-Q-wave myocardial infarction.
- CEO
- Albert David Friesen
- IPO
- 2004
- Employees
- 23
- HQ
- Winnipeg, MB, CA
Price Chart
- Market Cap
- $6.99M
- P/E
- -2.00
- P/S
- 0.43
- P/B
- 1.06
- EV/EBITDA
- -3.20
- Div Yield
- 0.00%
- Gross Margin
- 39.68%
- Op Margin
- -21.07%
- Net Margin
- -21.74%
- ROE
- -44.51%
- ROIC
- -49.00%
- Revenue
- $28.83M · 31.61%
- Net Income
- $-7,091,215 · -582.50%
- EPS
- $-0.68 · -582.73%
- Op Income
- $-6,882,385
- FCF YoY
- -187.70%
- 52W High
- $0.97
- 52W Low
- $0.67
- 50D MA
- $0.77
- 200D MA
- $0.82
- Beta
- 1.06
- Avg Volume
- 275
Get TickerSpark's AI analysis on MCUJF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MCUJF coverage
Recent articles, reports, and earnings notes.
No research on MCUJF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MCUJF report →Similar companies
Peers in the same neighborhood.